Any condition listed in K80.2 with cholecystitis (chronic) Cholecystitis with cholelithiasis NOS

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

cholecystitis | gall bladder inflammation

Laryngitis, chronic, with tracheitis (chronic) Tracheitis, chronic, with laryngitis

Chronic:bronchitis NOS | tracheitis | tracheobronchitis

Emphysema (diffuse)(chronic) | Obliterative bronchiolitis (chronic)(subacute) | Pulmonary fibrosis (chronic) | due to inhalation of chemicals, gases, fumes and vapours

Primary endpoint: Physician-diagnosed ILI (> 38°C and cough or sore throat) Secondary endpoint: Morbidity in elderly Clinical effectiveness against ILI in mass vaccination vs. comparison communities Kindergarten age: 60.9% (2.56 times fewer cases), p< 0.01 School age: 68.8% (3.2 times fewer cases), p< 0.01 Kindergarten and school age: 63.7%, p< 0.01 Morbidity rates for influenza-associated diseases among unvaccinated, non-institutionalized elderly in targeted vs. control communities during 2001/02 influenza season ILI: 0.07 vs. 0.24%, p< 0.01 Pneumonia: 0.1 vs. 0.26%, p< 0.01 Bronchial asthma (exacerbation): 0.09 vs. 0.23%, p< 0.01 Chronic bronchitis (exacerbation): 0.19 vs. 0.3 ...[+++]3%, p< 0.01 Cardiovascular disease: 0.49 vs. 1.65%, p< 0.01 Diabetes mellitus (exacerbation): 0.06 vs. 0.14%, p< 0.01 GI disease: 0.06 vs. 0.11%, p< 0.01 Chronic pyelonephritis (exacerbation): 0.07 vs. 0.12%, p< 0.05 Pancreatitis: 0.09 vs. 0.14%, p< 0.05 Rheumatoid arthritis: 0.17 vs. 0.13%, p< 0.05 Cholecystitis: 0.2 vs. 0.18%, p< 0.05 Morbidity rates among elderly in targeted vs. control communities off season (Aug – Sep 2002) No significant difference for all diseases, except: Cardiovascular disease: 0.74 vs. 1.04%, p< 0.01 Rheumatoid arthritis: 0.04 vs. 0.02%, p< 0.05